At Verona Pharma our vision is to become a leader in developing and commercializing innovative treatments to improve the health and quality of life of the millions of people affected by chronic respiratory diseases.
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
Our proprietary lead candidate, RPL554, is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma.
RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), that act as both a bronchodilator and an anti-inflammatory agent in a single compound. There is no therapy currently available that acts as both a bronchodilator and anti-inflammatory in a single compound for the treatment of respiratory diseases. We believe RPL554 has the potential to be the first novel type of bronchodilator in over forty years.
Verona Pharma is listed on the London Stock Exchange and is supported by a number of large, specialist healthcare focused investors from the UK, Europe and the US.
Realising multiple value creation opportunities with a unique respiratory product RPL554
27 June 2016
Targeting unmet needs
210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Our vision is to become a leader in developing innovative treatments for respiratory diseases with significant unmet medical needs. Our current focus is on RPL554, which we believe has the potential to become an important and novel treatment and standard of care for chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) and other respiratory diseases, including asthma.